Corcept Therapeutics Incorporated

CORTNASDAQHealthcare● Active

$73.79

+$1.17(+1.61%)

Market Cap$7.9B

P/E Ratio—

52W High$91

52W Low$28.66

Avg Volume1.4M

Open$72.88

Beta0.50

Free Cash Flow Financials Revenue

Corcept Therapeutics Incorporated (CORT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CORT · free cash flow · updated Jun 8, 2026

Core FCF metrics

CORT · FCF · TTM · margin & CAGR

Free cash flow was $141.8M for FY2025 (fiscal year ending 2025-12-31), down 27.6% year-over-year The FCF margin was 18.6%. Five-year CAGR stands at -1.2%.

FY2025 Free Cash Flow$141.8M▼ -27.6% YoY

Trailing 12M (TTM)$119.8Mtrailing 4 quarters sum

FCF Margin18.6%$141.8M ÷ revenue

3-Year CAGR+5.7%FY2022 → FY2025

5-Year CAGR-1.2%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CORT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$142.0M(0M)$141.8M▼ 27.6%18.6%

FY2024$198.1M(2M)$195.9M▲ +54.4%29.0%

FY2023$127.0M(0M)$126.9M▲ +5.8%26.3%

FY2022$120.3M(0M)$119.9M▼ 28.4%29.8%

FY2021$167.9M(0M)$167.4M▲ +11.1%45.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CORT · P/FCF · FCF yield · FCF per share

Corcept Therapeutics Incorporated (CORT) trades at a FCF yield of 1.49% and a price-to-free-cash-flow ratio of 64.2x. FCF per share stands at $1.15, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

1.49%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.15

TTM FCF ÷ Shares Outstanding

Price / FCF

x64.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x66.5

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CORT · cash flow statement · operating / investing / financing

For FY2025, Corcept Therapeutics Incorporated generated $142.0M in operating cash flow and spent 0M in capital expenditures, yielding $141.8M in free cash flow.

Operating Activities

+$142.0M

Cash from core business operations

2025-12-31

Investing Activities

+$69.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$220.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($142.0M) − |CapEx| (0M) = FCF ($141.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CORT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Corcept Therapeutics IncorporatedYOU

CORT

$141.8M-27.6%18.6%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Corcept Therapeutics Incorporated (CORT) reported free cash flow of $141.8M for FY2025 (fiscal year ending 2025-12-31), down 27.6% year-over-year. The FCF margin was 18.6%.

Based on available data, Corcept Therapeutics Incorporated has maintained positive free cash flow for at least 11 fiscal year(s). FCF peaked at $195.9M in FY2024. The 5-year CAGR stands at -1.2%.

Corcept Therapeutics Incorporated's FCF yield is 1.49% and price-to-FCF ratio is 64.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CORT free cash flow · 8 questions

Corcept Therapeutics Incorporated free cash flow was $141.8M for FY2025, down 27.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $119.8M.

CORT free cash flowCORT FCFCORT FCF 2025CORT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Corcept Therapeutics Incorporated · Corcept Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026